12.76
-27.62%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Janux Therapeutics
From its filings with the US Securities and Exchange Commission
Janux Therapeutics is based in San Diego, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker JANX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $10.0m and a net loss of $113.6m. At that date it held total assets of $1.00bn and shareholders' equity of $956.8m.
We are an innovative clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying our proprietary technologies to our Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. The goal of our TRACTr and TRACIr platforms is to provide cancer patients with safe and effective therapeutics that direct and guide their immune system to eradicate tumors while minimizing safety concerns. Our initial focus is on developing a novel class of TRACTr therapeutics designed to target clinically validated TCE drug targets, while overcoming the liabilities associated with prior generations of TCEs. While TCE therapeutics have displayed potent anti-tumor activity in hematological cancers, developing TCEs to treat solid tumors has faced challenges due to the limitations of prior TCE technologies, namely (i) on-target healthy tissue immune activation that contributes to cytokine release syndrome (CRS) and healthy tissue toxicity and (ii) poor pharmacokinetics (PK) leading to short half-life.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 11 Jun 2021
- Employees
- 109
- Website
- januxrx.com ↗
- Head office
- 10955 VISTA SORRENTO PARKWAY, SAN DIEGO, CA, 92130
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. Ronald BarrettIndependent Chairman of the Board$416,070
- Dr. David CampbellPresident, Chief Executive Officer, Founder, Director, since 2017$9.0m
- Dr. Thomas DiraimondoCo-Founder, Chief Scientific Officer, since 2024$3.4m
- Mr. Charles WinterChief Technical Officer$1.6m
- Mr. Andy MeyerChief Business Officer
- Ms. Janeen DoyleChief Corporate and Business Development Officer
- Dr. Zachariah MciverChief Medical Officer
- Ms. Vickie CappsIndependent Director$399,032
- Mr. Eric DobmeierIndependent Director$997,406
- Dr. Sheila GujrathiIndependent Director$384,032
- Ms. Natasha HerndayIndependent Director$997,406
- Mr. Winston KungIndependent Director$391,532
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 59
- Environment
- 62
- Social
- 74
- Governance
- 41
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Janux Therapeutics focuses on preclinical biopharmaceutical development with Tumor Activated T Cell Engager platform technology.
- Janux Therapeutics has a pipeline including PSMA-TRACTr, EGFR-TRACTr, and TROP2-TRACTr targeting validated cancer targets.
- Janux Therapeutics employs 109 full-time employees in San Diego, California, supporting its biotechnology operations.
Weaknesses
- Janux Therapeutics has a preclinical stage with no approved products or revenue streams.
- Janux Therapeutics has 60 full-time employees as reported in its business description.
- Janux Therapeutics went public on 11 June 2021 with limited market presence.
Opportunities
- Janux Therapeutics can expand its pipeline targeting PSMA, EGFR, and TROP2 in prostate cancer treatments.
- Janux Therapeutics can leverage TRACIr program targeting PD-L1xCD28 for new therapeutic applications.
- Janux Therapeutics can develop partnerships with pharmaceutical companies for clinical trials.
Threats
- Janux Therapeutics faces competition from other biotech firms in the Health Care sector.
- Janux Therapeutics must navigate regulatory challenges in the biopharmaceutical industry.
- Janux Therapeutics has no approved products, increasing market entry risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.